

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (currently amended) A transgenic mouse non-human animal whose genome comprises a polynucleotide encoding human ICAM-1 domains D1 and D2.
2. (currently amended) A transgenic mouse non-human animal according to claim 1, wherein said polynucleotide encodes human ICAM-1 domains D1 and D2 and one or more mouse host non-human animal ICAM-1 domains D3, D4 or D5.
3. (currently amended) A transgenic mouse non-human animal according to claim 2, wherein said polynucleotide encodes human ICAM-1 domains D1 and D2 and mouse host non-human animal ICAM-1 domains D3, D4 and D5.
4. (currently amended) A transgenic mouse non-human animal according to claim 1 any of claims 1 to 3, wherein said polynucleotide comprises one or more of the following polynucleotide sequences:
 - (a) a polynucleotide sequence having at least 90% ,more preferably 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the polynucleotide sequence of SEQ ID No:2;
 - (b) a polynucleotide sequence having at least 90% ,more preferably 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the polynucleotide sequence of SEQ ID No:3;
 - (c) a polynucleotide sequence encoding a polypeptide sequence having at least 90% ,more preferably 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the polypeptide sequence of SEQ ID No:5;

(d) a polynucleotide sequence encoding a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polypeptide sequence of SEQ ID No:6;

(e) a polynucleotide fragment of SEQ ID No:1 ~~(or a sequence with at least 90%, or more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it)~~ encoding human ICAM-1 domains D1 and D2; and

(f) a polynucleotide sequence encoding a polypeptide fragment of SEQ ID No:4 ~~(or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it)~~ comprising human ICAM-1 domains D1 and D2.

5. (currently amended) A transgenic ~~non-human animal~~ mouse according to claim 1 ~~any of claims 1 to 4~~, whose genome further comprises a regulatory sequence capable of directing expression of said polynucleotide in cells ~~and/or tissues~~ of the respiratory tract.

6. (currently amended) A transgenic mouse ~~non-human animal~~ according to claim 5, wherein said regulatory sequence is a promoter selected from the group consisting of CMV, SV40, human surfactant protein C (SPC) or Clara cell 10KDa secretory (CC10).

7. (currently amended) A transgenic ~~non-human animal~~ mouse according to claim 1 ~~any one of claims 1 to 4~~, which expresses an ICAM-1 polypeptide comprising human ICAM-1 domains D1 and D2.

8. (currently amended) A transgenic ~~non-human animal~~ mouse according to claim 7, which expresses a chimaeric ICAM-1 polypeptide comprising human ICAM-1 domains D1 and D2.

9. (currently amended) A transgenic ~~non-human animal~~ mouse according to claim 8, which expresses a chimaeric ICAM-1 polypeptide comprising one or more of the following polypeptide sequences:

- (a) a polypeptide fragment of SEQ ID No:4 (~~or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it~~) comprising human ICAM-1 domains D1 and D2;
- (b) a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity with the polypeptide sequence of SEQ ID No:5; and
- (c) a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity with the polypeptide sequence of SEQ ID No:6.

10. (currently amended) A transgenic ~~non-human animal~~ mouse according to claim 9, wherein said chimaeric ICAM-1 polypeptide comprises one or more of ~~host non-human animal~~ mouse ICAM-1 domains D3, D4 and D5.

11. (currently amended) A transgenic ~~non-human animal~~ mouse according to claim 10, wherein said chimaeric ICAM-1 polypeptide comprises ~~host non-human animal~~ mouse ICAM-1 domains D3, D4, and D5.

12. (currently amended) A transgenic ~~non-human animal~~ mouse according to claim 8 ~~any of claims 9 to 11~~, wherein said chimaeric ICAM-1 polypeptide is expressed in the cells and/or tissues of the respiratory tract.

13. (currently amended) A transgenic ~~non-human animal~~ mouse according to claim 8 ~~any of claims 8 to 12~~, wherein said chimaeric ICAM-1 polypeptide is capable of binding and supporting major group human rhinovirus (HRV) HRV infection.

14. – 16 (canceled)

17. A transgenic ~~animal~~ mouse according to ~~any of claims 1 to 6, claim 1~~ wherein ~~said animal is a mouse and~~ said polynucleotide comprises one or more of the following polynucleotide sequences:

- (a) a polynucleotide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polynucleotide sequence of SEQ ID No:8;
 - (b) a polynucleotide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polynucleotide sequence of SEQ ID No:9;
 - (c) a polynucleotide sequence having at ~~lease~~ least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polynucleotide sequence of SEQ ID No:10;
 - (d) a polynucleotide sequence encoding a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polypeptide sequence of SEQ ID No:11;
 - (e) a polynucleotide sequence encoding a polypeptide sequence having at least 90% ~~or more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polypeptide sequence of SEQ ID No:12;
 - (f) a polypeptide sequence encoding a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polypeptide sequence of SEQ ID No:13;
 - (g) a polynucleotide fragment of SEQ ID No:7 ~~(or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it)~~ encoding one or more of murine ICAM-1 domains D3, D4 and D5;
 - (h) a polynucleotide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polynucleotide sequence of SEQ ID No:14; and
 - (i) a polynucleotide encoding a polypeptide having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polypeptide sequence of SEQ ID No:15.
18. (currently amended) A transgenic animal mouse according to ~~any of claims 7 to 13~~ claim 7, wherein ~~said animal is a mouse and said chimaeric ICAM-1~~ polypeptide comprises one or more of the following polypeptide sequences:

- (a) a polypeptide fragment of SEQ ID No:7 (~~or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it~~) comprising one or more of murine ICAM-1 domains D3, D4 and D5;
- (b) a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity with the polypeptide sequence of SEQ ID No:11;
- (c) a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity with the polypeptide sequence of SEQ ID No:12;
- (d) a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity with the polypeptide sequence of SEQ ID No:13; and
- (e) a polypeptide sequence having at least 90% ,~~more preferably 95%, 96%, 97%, 98%, 99% or 100%~~ sequence identity to the polypeptide sequence of SEQ ID No:15.

19 - 22. (canceled)

23. (currently amended) A chimaeric transgene An isolated polynucleotide comprising a polynucleotide sequence encoding human ICAM-1 domains D1 and D2 and according to any of claims 19 to 22, further comprising a regulatory sequence capable of directing expression of said polynucleotide in cells and/or tissues of the murine respiratory tract.

24. (currently amended) A vector comprising the transgene a polynucleotide according to claim 23 any of claims 19 to 23.

25. (currently amended) A murine cell stably transfected or transformed with a polynucleotide according to claim 23 the transgene according to any of claims 19 to 23.

26. (canceled)

27. (currently amended) A method of producing a transgenic mouse according to claim 26, wherein the transgene according to any of claims 19 to 23 is introduced, comprising introducing a polynucleotide according to claim 23 into non-human animal murine ES cells using electroporation, retroviral vectors or lipofection for gene transfer.

28. (canceled)

29. A method of screening test agents for use in the treatment of a condition associated with ~~or exacerbated by~~ major group HRV infection, the method comprising administering a test agent to a transgenic mouse according to claim 1 non-human animal as defined in any one of claims 1 to 18, and determining whether the test substance (i) prevents or delays the onset of the condition or (ii) ~~treats or~~ alleviates the condition.